Bisphosphonates: Clinical experience

Oncologist

Volumn 9, Issue SUPPL. 4, 2004, Pages 14-27

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Bone metastases; Pamidronate; Phase III; Skeletal complications; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; MITOXANTRONE; PAMIDRONIC ACID; PLACEBO; PREDNISONE; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MULTIPLE MYELOMA; MYALGIA; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; SPINAL CORD COMPRESSION; VOMITING;

BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; ENDPOINT DETERMINATION; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; SPINAL CORD COMPRESSION;

EID: 5444262558     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90004-14     Document Type: Conference Paper

References (55)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no. 5. Lyon: IARCPress, 2001. Available at: http://www-dep.iarc.fr/globocan/cdrom.htm. Accessed 06/21/04.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(suppl 8):1588-1594.
4. Zekri J, Ahmed N, Coleman RE et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379-382.
5. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
6. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
7. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882.
8. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
9. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:1-7.
10. Garnero P, Buchs N, Zekri J et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000;82:858-864.
11. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88(suppl 12):2919-2926.
12. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop 2003;415(suppl):S138-S147.
13. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
14. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002;55:210-224.
15. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-1411.
16. Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat 2004;14:5-21.
17. Major PP, Cook RJ, Chen BL et al. Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates - from the laboratory to the patient, March 24-26, 2004, Davos, Switzerland.
18. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25(suppl 1):S10-S18.
19. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-1120.
20. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000;56:554-562.
21. Cook RJ, Lawless JF. Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics 1996;52:1311-1323.
22. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
23. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057. Erratum in: J Clin Oncol 2004;22:1351.
24. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
25. Windeler J, Lange S. Events per person year - a dubious concept. BMJ 1995;310:454-456.
26. Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane Review). In: The Cochrane Library, Issue 1. Hoboken, NJ: John Wiley and Sons, Ltd, 2004.
27. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74.
28. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer 2001;88:701-707.
29. Hortobágyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-2044.
30. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854.
31. Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-3392.
32. Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14:2552-2559.
33. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
34. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-1137.
35. Kohno N, Aogi K, Minami H et al. A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Presented at the 40th annual meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA.
36. Hortobágyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
37. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004;9(suppl 4):28-37.
38. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
39. Major PP, Cook RJ, Chen BL et al. Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc Am Soc Clin Oncol 2003;22:762.
40. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
41. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-87.
42. Elomaa I, Kylmälä T, Tammela T et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992;24:159-166.
43. Kylmala T, Taube T, Tammela TL et al. Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997;76:939-942.
44. Strang P, Nilsson S, Brandstedt S et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997;17:4717-4721.
45. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-3342.
46. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-1311.
47. Mason MD. Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873). Proc Am Soc Clin Oncol Late Breaking Booklet 2004;16.
48. Small EJ, Smith MR, Seaman JJ et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-4284.
49. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
50. Saad F, Gleason D, Murray R et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. J Urol 2003;169(suppl):394.
51. Coleman R, Rosen L, Gleason DM et al. Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumours. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates - from the laboratory to the patient, March 24-26, 2004, Davos, Switzerland.
52. Saad F, Gleason D, Murray R et al. Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Presented at the XIXth Congress of the European Association of Urology, 24-27 March 2004, Vienna, Austria.
53. Weinfurt KP, Li Y, Castel LD et al. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2002;13(suppl 5):180.
54. Lipton A, Small E, Saad F et al. The new bisphosphonate, Zometa® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002;20(suppl 2):45-54.
55. Lipton A, Seaman J, Zheng M. Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates - from the laboratory to the patient, March 24-26, 2004, Davos, Switzerland.